Greenwich Stock Valuation

GLSI
 Stock
  

USD 8.85  0.37  4.36%   

Do you want to know what the current value of Greenwich Lifesciences is today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Greenwich Lifesciences, is its stock price multiplied by the total number of shares outstanding, calculating Greenwich Lifesciences' enterprise value requires a different approach. It uses Greenwich Lifesciences' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
The current Enterprise Value is estimated to increase to about 305.1 M, while Free Cash Flow is projected to decrease to (4.4 M).
Greenwich Lifesciences retains a regular Real Value of $26.13 per share. The prevalent price of the firm is $8.85. At this time, the firm appears to be undervalued. Our model calculates the value of Greenwich Lifesciences from evaluating the firm fundamentals such as Return On Asset of (10.28) %, return on equity of (16.78) %, and Shares Owned by Insiders of 77.64 % as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage locking in undervalued assets and disposing overvalued assets since, at some point, asset prices and their ongoing real values will come together.
  
Refresh
Greenwich Lifesciences Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Greenwich Lifesciences's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Greenwich Most Recent Valuation Data

Price Book
5.36
Enterprise Value
84.8 M
Undervalued
Today 8.85
Please note that Greenwich Lifesciences' price fluctuation is somewhat reliable at this time. Calculation of the real value of Greenwich Lifesciences is based on 1 month time horizon. Increasing Greenwich Lifesciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Greenwich Lifesciences is useful when determining the fair value of the Greenwich stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Greenwich Lifesciences. Since Greenwich Lifesciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Greenwich Stock. However, Greenwich Lifesciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
26.13
Real Value
35.39
Upside
Estimating the potential upside or downside of Greenwich Lifesciences helps investors to forecast how Greenwich stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Greenwich Lifesciences more accurately as focusing exclusively on Greenwich Lifesciences' fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimated ValueHigh
0.448.8118.07
Details
1 Analysts
Consensus
LowTarget PriceHigh
78.0078.0078.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Greenwich Lifesciences' intrinsic value based on its ongoing forecasts of Greenwich Lifesciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Greenwich Lifesciences' closest peers. When choosing an evaluation method for Greenwich Lifesciences, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Greenwich Valuation Drivers Correlation

Many accounts on the financial statements of Greenwich Lifesciences are highly interrelated and sometimes correlated. Consequently, when conducting Greenwich's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Greenwich
Click cells to compare fundamentals

Greenwich Valuation Trend

Knowing Greenwich Lifesciences' actual value is paramount for traders to make sound investment determinations. Greenwich Lifesciences' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Greenwich Lifesciences' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Greenwich Lifesciences' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Greenwich Market Cap

Greenwich Lifesciences is one of the top stocks in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 211.02 Million. Greenwich Lifesciences totals roughly 105.51 Million in market capitalization claiming about 50% of stocks in Biotechnology industry.
Capitalization  Workforce  Total debt  Valuation  Revenue

Greenwich Lifesciences Total Value Analysis

Greenwich Lifesciences is currently projected to have valuation of 126.27 M with market capitalization of 105.51 M, debt of 635.15 K, and cash on hands of 27.2 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Greenwich Lifesciences fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
126.27 M105.51 M635.15 K27.2 M

Greenwich Lifesciences Asset Utilization

One of the ways to look at asset utilization of Greenwich is to check how much profit was generated for every dollar of assets it reports. Greenwich Lifesciences retains a negative application of resources of -10.28 (percent), losing $0.1 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Greenwich Lifesciences shows how discouraging it operates for each dollar spent on its resources.

Greenwich Lifesciences Ownership Allocation (%)

The market capitalization of Greenwich Lifesciences is $105.51 Million. Greenwich Lifesciences retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 77.64 (percent) of Greenwich Lifesciences outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 Ownership % 
      Values 

Greenwich Lifesciences Profitability Analysis

Net Loss for the year was (4.57 M).
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Greenwich Lifesciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Greenwich Lifesciences and how it compares across the competition.

About Greenwich Lifesciences Valuation

The equity valuation mechanism determines the current worth of Greenwich Lifesciences on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Greenwich Lifesciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Greenwich Lifesciences based exclusively on its fundamental and basic technical indicators. By analyzing Greenwich Lifesciences's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Greenwich Lifesciences's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Greenwich Lifesciences. We calculate exposure to Greenwich Lifesciences's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Greenwich Lifesciences's related companies.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas. Greenwich Lifesciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Greenwich Lifesciences Quarterly Enterprise Value

226.9 Million

Share

Greenwich Lifesciences Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Greenwich Lifesciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio70.63
Enterprise Value To Ebitda-27.48

Greenwich Lifesciences Current Valuation Indicators

Valuation refers to the process of determining the present value of Greenwich Lifesciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Greenwich we look at many different elements of the entity such as Greenwich's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Greenwich Lifesciences' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Greenwich Lifesciences' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Greenwich Lifesciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Greenwich Lifesciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Greenwich Lifesciences' worth.
Please check Risk vs Return Analysis. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
110.2 M
Return On Assets
-0.15
Return On Equity
-0.24
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.